Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1457301

USP

Naproxen

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula lineal:
CH3OC10H6CH(CH3)CO2H
Número de CAS:
22204-53-1
Peso molecular:
230.26
Beilstein:
3591068
Número MDL:
MFCD00010500
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750529
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

naproxen

fabricante / nombre comercial

USP

técnicas

HPLC: suitable
gas chromatography (GC): suitable

mp

152-154 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O

InChI

1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

Clave InChI

CMWTZPSULFXXJA-VIFPVBQESA-N

Información sobre el gen

human ... PTGS1(5742) , PTGS2(5743)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Dexamethasone Compounded Oral Suspension
  • Naproxen
  • Naproxen Compounded Oral Suspension
  • Naproxen Delayed-Release Tablets
  • Naproxen Oral Suspension
  • Naproxen Tablets
  • Terazosin Tablets

Acciones bioquímicas o fisiológicas

Inhibidor no selectivo de la ciclooxigenasa (COX-1 y COX-2).

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

PHR1165

Naproxen sodium, Pharmaceutical Secondary Standard; Certified Reference Material

N0250000

Naproxen, European Pharmacopoeia (EP) Reference Standard

Y0000399

Naproxen (racemic), European Pharmacopoeia (EP) Reference Standard

Y0000631

Naproxen impurity L, European Pharmacopoeia (EP) Reference Standard

1457403

Naproxen sodium, United States Pharmacopeia (USP) Reference Standard

1457312

Naproxen Related Compound A, United States Pharmacopeia (USP) Reference Standard

1457425

Naproxen Related Compound L, United States Pharmacopeia (USP) Reference Standard

08129

6-Methoxy-2-naphthol, pharmaceutical impurity standard

79584

2-Ethyl-6-methoxynaphthalene, pharmaceutical impurity standard

80713

(1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol, pharmaceutical impurity standard

82170

(R)-Naproxen, pharmaceutical impurity standard

07506

(S)-Naproxen ethyl ester, pharmaceutical impurity standard

80822

(S)-Naproxen methyl ester, pharmaceutical impurity standard

80816

(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80821

(2S)-2-(5-Iodo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80818

(2S)-2-(5-Bromo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

07503

2-Bromo-6-methoxynaphthalene, pharmaceutical impurity standard

07499

2-Methoxynaphthalene, pharmaceutical impurity standard

07547

6-Methoxy-2-naphthoic acid, pharmaceutical impurity standard

BP435

Naproxen, British Pharmacopoeia (BP) Reference Standard

1457436

Naproxen Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR2254

Naproxen 1,2,3 Propanetriol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2256

Naproxen 1,3-Butylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2219

Naproxen 1,2 Propylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2248

Naproxen 2,3-Butylene Glycol Ester, pharmaceutical secondary standard

PHR2257

Naproxen Isopropyl Ester, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2524

Naproxen Impurity N, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2525

Naproxen Impurity M, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2527

Naproxen Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2526

Naproxen Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

Naproxen Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2523

Naproxen Related Compound L, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

Naproxen Related Compound K, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2521

Naproxen Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

Naproxen Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

Naproxen Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

Naproxen Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Palabra de señalización

Warning

Clasificaciones de peligro

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

Órganos de actuación

Respiratory system

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 6

1 of 6

Naproxen Related Compound A United States Pharmacopeia (USP) Reference Standard

USP

1457312

Naproxen Related Compound A

Naproxen sodium 98.0-102.0%

Sigma-Aldrich

M1275

Naproxen sodium

(R)-Naproxen pharmaceutical impurity standard

Supelco

82170

(R)-Naproxen

Naproxen impurity L European Pharmacopoeia (EP) Reference Standard

Y0000631

Naproxen impurity L

Naproxen 98%

Sigma-Aldrich

284785

Naproxen

Acetaminophen United States Pharmacopeia (USP) Reference Standard

USP

1003009

Acetaminophen

Christopher Derry et al.
The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)
Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg
Marta L Capone et al.
Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)
We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5
Larisa Kovacevic et al.
Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)
A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4
Anke Prudic et al.
Molecular pharmaceutics, 11(11), 4189-4198 (2014-10-09)
The incorporation of poorly soluble active pharmaceutical ingredients (APIs) into excipients (e.g., polymers) to formulate an amorphous solid dispersion is a promising strategy to improve the oral bioavailability of the API. The application of copolymer excipients allows access to combinations
Tarjinder Sahota et al.
Toxicology and applied pharmacology, 278(3), 209-219 (2014-03-29)
The assessment of safety in traditional toxicology protocols relies on evidence arising from observed adverse events (AEs) in animals and on establishing their correlation with different measures of drug exposure (e.g., Cmax and AUC). Such correlations, however, ignore the role
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico